TY - JOUR AU - Passiglia, Francesco AU - Raez, Luis E. AU - Rolfo, Christian PY - 2018 TI - Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer? JF - Journal of Thoracic Disease; Vol 10, Supplement 9 (April 24, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - In the N Engl J Med , Soria and colleagues have recently reported the results of the phase III randomized FLAURA trial (1), comparing osimertinib with first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) and activating EGFR -mutations. UR - https://jtd.amegroups.org/article/view/20029